找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Breast Cancer Chemosensitivity; Dihua Yu,Mien-Chie Hung Book 2007 The Editor(s) (if applicable) and The Author(s), under exclusive license

[復(fù)制鏈接]
樓主: 小費
21#
發(fā)表于 2025-3-25 05:29:30 | 只看該作者
22#
發(fā)表于 2025-3-25 10:55:50 | 只看該作者
Estrogen Receptors in Resistance to Hormone Therapy,omeostasis and receptor coregulator proteins. Additionally, the role of nonclassical ERα signaling through growth factor receptors and the subsequent downstream-initiated signaling, and the role of the progesterone receptors will be discussed.
23#
發(fā)表于 2025-3-25 11:48:19 | 只看該作者
24#
發(fā)表于 2025-3-25 17:24:23 | 只看該作者
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance,ors even as a monomer..–. The binding of ErbB2 to other ErbB receptors results in increased signaling potency of the dimerized receptors through several means, including increased ligand affinity, increased coupling efficiency to signaling molecules, and decreased rate of receptor internalization..–.
25#
發(fā)表于 2025-3-25 22:11:09 | 只看該作者
Book 2007emotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment..
26#
發(fā)表于 2025-3-26 02:20:42 | 只看該作者
27#
發(fā)表于 2025-3-26 05:55:37 | 只看該作者
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer,rld in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease. To offer more effective and less toxic treatment, selecting therapi
28#
發(fā)表于 2025-3-26 12:22:23 | 只看該作者
29#
發(fā)表于 2025-3-26 15:13:47 | 只看該作者
Therapy-Induced Apoptosis in Primary Tumors,d by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the precl
30#
發(fā)表于 2025-3-26 19:54:05 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-18 14:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
广平县| 慈利县| 罗山县| 兰坪| 绥芬河市| 杭锦后旗| 河间市| 大连市| 黔南| 高雄市| 英德市| 绥滨县| 甘南县| 偃师市| 南平市| 新蔡县| 开江县| 广安市| 竹山县| 西林县| 偏关县| 开远市| 白山市| 闵行区| 双江| 宜宾县| 秦安县| 寻乌县| 潞西市| 吉林市| 新邵县| 张掖市| 山东| 龙游县| 惠来县| 东阿县| 玉龙| 荔波县| 凤山市| 涡阳县| 新密市|